Citations

Clear

6055 citation(s) found for "Vu, Peter".

Multicenter analysis of flow diversion for recurrent/persistent intracranial aneurysms after stent-assisted coiling
Salem, Mohamed M. , Helal, Ahmed , Gajjar, Avi A. , Sioutas, Georgios S. , Heiferman, Daniel M. , Lylyk, Iván , Levine, Alex, Salih, Mira , Abbas, Rawad , Saber, Hamidreza , Lanzino, Giuseppe, Brinjikji, Waleed , Tanweer, Omar , Spiotta, Alejandro M , Park, Min S. , Dumont, Aaron S. , Kim, Louis J. , Kan, Peter , Wolfe, Stacey Q , Raz, Eytan , Shapiro, Maksim , Siddiqui, Adnan H. , Ares, William J. , Ogilvy, Christopher S. , Srinivasan, Visish M. , Starke, Robert M., Ducruet, Andrew F. , Tjoumakaris, Stavropoula , Jankowitz, Brian T. , Albuquerque, Felipe C , Nelson, Peter Kim , Riina, Howard A. , Lylyk, Pedro , Jabbour, Pascal , Burkhardt, Jan Karl, Heiferman, Daniel M , Lylyk, Ivan , Desai, Sohum , Borg, Nicholas , Brinjikji, Waleed , Spiotta, Alejandro M , Arthur, Adam Stephen , Levitt, Michael R , Kan, Peter , Hassan, Ameer E , Wolfe, Stacey Quintero , Raz, Eytan , Siddiqui, Adnan H , Ares, William J , Ogilvy, Christopher S , Tjoumakaris, Stavropoula , Jankowitz, Brian , Albuquerque, Felipe C , Jabbour, Pascal , Burkhardt, Jan‐Karl , Naamani, Kareem El , Renieri, Leonardo , Monteiro, Andre , Abdelsalam, Ahmed, Catapano, Joshua S , Lanzino, Giuseppe , Kim, Louis J. , Levitt, Michael R. , Hassan, Ameer E , Limbucci, Nicola , Colby, Geoffrey P. , Hanel, Ricardó A. , Levy, Elad I. , Thomas, Ajith J , Lopes, Demetrius K.

Mayo Clinic

Journal of NeuroInterventional Surgery | March 27, 2025 | Volume: 18 | Issue: 2 | Pages: 324-331

10.1136/jnis-2024-022422 | PMID 40139781 Get It

Background Flow-diverter stents (FDS) have become the standard of care for a wide range of intracranial aneurysms, but their efficacy/safety in the context of recurrent/recanalized aneurysms following stent-assisted coiling (SAC) is not well established. We evaluate the outcomes of FDS retreatment in a large multicenter cohort. Methods We retrospectively analyzed data from 118 patients across 22 institutions who underwent FDS retreatment for recurrent/persistent aneurysms after SAC (2008–22). The primary outcome was angiographic occlusion status at last follow-up, categorized as complete (100%), near-complete (90–99%), or incomplete (<90%) occlusion. Secondary outcomes included procedural complications and clinical outcomes measured by the modified Rankin Scale (mRS). Results A total of 118 patients (median age 57, 74.6% female) with median follow-up of 15.3 months were identified. Complete occlusion was achieved in 62.5% and near-complete occlusion in 25%. FDS deployment within the pre-existing stent was successful in 98.3% of cases. Major complications occurred in 3.4% of cases, including postoperative aneurysmal rupture with resultant mortality (1.6%) and thromboembolic events with long-term disability (1.6%). Favorable clinical outcomes (mRS 0–2) were observed in 95.1% of patients. Wider aneurysm neck diameter was a significant predictor of incomplete occlusion (adjusted OR (aOR) 1.23 per mm, P=0.044), with male sex trending towards association with non-occlusion (aOR 3.2, P=0.07), while baseline hypertension was associated with complete occlusion (aOR 0.32, P=0.048). Conclusions FDS treatment for recurrent/residual aneurysms after SAC represents a viable treatment option for these challenging cases with acceptable safety and reasonable occlusion rates, although lower than de novo FDS occlusion rates.
2024 American College of Rheumatology ( ACR ) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Rovin, Brad H. , Alvarado, Anthony, Aranow, Cynthia , Broder, Anna , Chowdhary, Vaidehi , Contreras, Gabriel, Felix, Christele, Gibson, Keisha L. , Hersh, Aimee O. , Kalunian, Kenneth , Rollins, Brandi , Smith, Benjamin J. , Thomas, Asha , Timlin, Homa , Ward, Michael D. , Bartels, Christie M. , Cunha, Joanne S., DeQuattro, Kimberly , Figueroa‐Parra, Gabriel , Greco, Jessica , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kelly V. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Ferucci, Elizabeth D , Hersh, Aimee O , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Kirou, Kyriakos A , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Rovin, Brad H , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Barnado, April , Contreras, Gabriel, Ferucci, Elizabeth D. , Izmirly, Peter , Kamen, Diane L. , Rollins, Brandi, Thomas, Asha, Azzam, Muayad , Fava, Andrea , Garg, Shivani , Cuéllar‐Gutiérrez, María C. , Kawtharany, Hassan , Kirou, Kyriakos A. , Mustafa, Reem A

Mayo Clinic

Arthritis Care & Research | March 26, 2025 | Volume: 77 | Issue: 9 | Pages: 1045-1065

10.1002/acr.25528 | PMID 40127995 Get It

Objective The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis. Methods The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation. Results We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response. Conclusion This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration
Schnabel, Renate B. , Schutte, Aletta E. , Buckley, Claire , Cameron, Alan C. , Damasceno, Albertino , Diederichsen, Søren Zöga , Doehner, Wolfram , Joung, Boyoung , Hankey, Graeme J. , Lobban, Trudie , Mairesse, Georges H. , Svendsen, Jesper Hastrup , Tieleman, Robert G , Wang, Ji‐Guang , Niiranen, Teemu J , Schnabel, Renate B , Schutte, Aletta E , Boriani, Giuseppe , Buckley, Claire , Cameron, Alan C , Damasceno, Albertino , Diederichsen, Søren Z , Doehner, Wolfram , Guo, Yutao , Hobbs, F D Richard , Joung, Boyoung , Hankey, Graeme J , Lip, Gregory Y H , Lobban, Trudie , Løchen, Maja-Lisa , Mairesse, Georges , Mbakwem, Amam , Noseworthy, Peter A , Steinhubl, Steven , Stergiou, George , Svendsen, Jesper Hastrup , Tieleman, Robert G , Wang, Ji-Guang , Poulter, Neil R , Healey, Jeffrey S , Freedman, Ben , Biton, Yitschak , Boriani, Giuseppe , Hobbs, Richard , Mbakwem, Amam , Noseworthy, Peter A. , Ntaios, George , Stergiou, George S. , Healey, Jeff S. , Freedman, Ben

Mayo Clinic

Circulation | March 24, 2025 | Volume: 151 | Issue: 12 | Pages: 863-877

10.1161/circulationaha.124.071047 | PMID 40127157 Get It

Hypertension is the leading modifiable risk factor for atrial fibrillation (AF) and is estimated to be present in >70% of AF patients. This Frontiers Review was prepared by 29 expert members of the AF-SCREEN International Collaboration to summarize existing evidence and knowledge gaps on links between hypertension, AF, and their cardiovascular sequelae; simultaneous screening for hypertension and AF; and the prevention of AF through antihypertensive therapy. Hypertension and AF are inextricably connected. Both are easily diagnosed, often silent, and frequently treated inadequately. Together, they additively increase the risk of ischemic stroke, heart failure, and many types of dementia, resulting in greater all-cause mortality, considerable disease burden, and increased health care expenditures. Automated upper arm cuff blood pressure devices with implemented technology can be used to simultaneously detect both hypertension and AF. However, positive screening for AF with an oscillometric blood pressure monitor still requires ECG confirmation. The current evidence suggests that high-risk individuals aged ≥65 years or with treatment-resistant hypertension could benefit from AF screening. Since antihypertensive therapy effectively lowers AF risk, particularly in individuals with left ventricular dysfunction, hypertension should be the key target for AF prediction and prevention rather than merely a comorbidity of AF. Nevertheless, several important gaps in knowledge need to be filled over the next years, including the ideal method and selection of patients for simultaneous screening of hypertension and AF and the optimal antihypertensive drug class and blood pressure targets for AF prevention.
Autosomal Dominant Polycystic Kidney Disease
Hanna, Christian , Dahl, Neera K. , Hanna, Christian , Dahl, Neera K , Chebib, Fouad T. , Harris, Peter C. , Torres, Vicente E.

Mayo Clinic

JAMA | March 24, 2025 | Volume: 333 | Issue: 19 | Pages: 1708

10.1001/jama.2025.0310 | PMID 40126492 Get It

Importance Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive development of kidney cysts and is the most common inherited kidney disorder worldwide. ADPKD accounts for 5% to 10% of kidney failure in the US and Europe, and its prevalence in the US is 9.3 per 10 000 individuals. Observations ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the PKD1 (78%) or PKD2 (15%) genes. Most persons with ADPKD have an affected parent, but de novo disease is suggested in 10% to 25% of families. More than 90% of patients older than 35 years have hepatic cysts, which may cause abdominal discomfort and occasionally require medical or surgical intervention. Hypertension affects 70% to 80% of patients with ADPKD, and approximately 9% to 14% develop intracranial aneurysms, which have a rupture rate of 0.57 per 1000 patient-years. Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age. The severity of kidney disease can be quantified using the Mayo Imaging Classification (MIC), which stratifies patients based on total kidney volume adjusted for height and age and ranges from 1A to 1E. Patients with MIC 1C to MIC 1E have larger kidneys because of more rapid growth (6%-10% per year) compared with those with MIC 1A and 1B (1%-5% per year) and have earlier progression to kidney replacement therapy, which occurs at a mean age of 58.4 years for MIC 1C, 52.5 years for MIC 1D, and 43.4 years for MIC 1E. Optimal management of ADPKD includes systolic blood pressure lower than 120 mm Hg for most patients, but lower than 110/75 mm Hg for patients with MIC 1C to 1E who have an estimated glomerular filtration rate (eGFR) greater than 60 mL/min/1.73 m 2 and are younger than 50 years, dietary sodium restriction (&amp;lt;2000 mg/d), weight management, and adequate hydration (&amp;gt;2.5 L daily). The vasopressin type 2 receptor antagonist tolvaptan reduces the annual rate of eGFR decline by 0.98 to 1.27 mL/min/1.73 m 2 and is indicated for patients with MIC 1C to 1E or an eGFR decline greater than 3 mL/min/1.73 m 2 per year to slow disease progression and delay the onset of kidney failure. Conclusion ADPKD is the most common genetic kidney disease worldwide and is characterized by progressive development of kidney cysts. Patients typically have hypertension and liver cysts, and 9% to 14% develop intracranial aneurysms. First-line treatment includes blood pressure control, dietary and weight management, and adequate hydration. Tolvaptan reduces the rate of eGFR decline for those at high risk of rapid progression to kidney failure.
PPM1M, a LRRK2-counteracting, phosphoRab12-preferring phosphatase with potential link to Parkinson’s disease
Chiang, Claire Y , Pratuseviciute, Neringa , Lin, Yu‐En , Adhikari, Ayan , Yeshaw, Wondwossen M , Flitton, Chloe , Sherpa, Pemba , Tonelli, Francesca , Lynch, Timothy , Siuda, Joanna , Pulyk, O. R. , Sherpa, Pemba L , Rektorova, Irena , Lynch, Timothy , Siuda, Joanna S. , Pulyk, Oleksandr , Bauer, Peter , Beetz, Christian , Dickson, Dennis W , Ross, Owen A , Wszolek, Z.K. , Klein, Christine , Zimprich, Alexander , Alessi, Dario R , Sammler, Esther M , Pfeffer, Suzanne R , Tonelli, Francesca , Rektorová, Irena , Rudzińska, Monika , Dickson, Dennis W. , Ross, Owen A. , Wszołek, Zbigniew K. , Klein, Christine , Zimprich, Alexander , Alessi, Dario R. , Sammler, Esther

Mayo Clinic

No container title available | March 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.19.644182 | PMID 40166354 Get It

Abstract Leucine-rich repeat kinase 2 (LRRK2) phosphorylates a subset of Rab GTPases that regulate receptor trafficking; activating mutations in LRRK2 are linked to Parkinson’s disease. Rab phosphorylation is a transient event that can be reversed by phosphatases, including PPM1H, that acts on phosphoRab8A and phosphoRab10. Here we report a phosphatome-wide siRNA screen that identified PPM1M as a phosphoRab12-preferring phosphatase that also acts on phosphoRab8A and phosphoRab10. Upon knockout from cells or mice, PPM1M displays selectivity for phosphoRab12. As shown previously for mice harboring LRRK2 pathway mutations, knockout of Ppm1m leads to primary cilia loss in striatal cholinergic interneurons. We have also identified a rare PPM1M mutation in patients with Parkinson’s disease that is catalytically inactive when tested in vitro and in cells. These findings identify PPM1M as a key player in the LRRK2 signaling pathway and provide a new therapeutic target for the possible benefit of patients with Parkinson’s disease. Teaser Parkinson’s linked Rab phosphorylation is reversed by PPM1M; the inactive D440N variant is implicated in rare patient cases.
A Validity Analysis of Text-to-Image Generative Artificial Intelligence Models for Craniofacial Anatomy Illustration
Haider, Syed Ali , Gomez-Cabello, Cesar A. , Borna, Sahar , Pressman, Sophia M. , Genovese, Ariana , Trabilsy, Maissa , Galvao, Andrea , Murray, Peter M. , Parte, Yogesh, Yu, Yunguo , Tao, Cui , Forte, Antonio J. , Gomez-Cabello, Cesar A , Borna, Sahar , Galvao, Andrea , Tao, Cui , Forte, Antonio Jorge , Pressman, Sophia , Haider, Syed A , Genovese, Ariana , Prabha, Srinivasagam , Aziz, Keith T

Mayo Clinic

Journal of Clinical Medicine | March 21, 2025 | Volume: 14 | Issue: 7 | Pages: 2136

10.3390/jcm14072136 | PMID 40217587 Get It

Background: Anatomically accurate illustrations are imperative in medical education, serving as crucial tools to facilitate comprehension of complex anatomical structures. While traditional illustration methods involving human artists remain the gold standard, the rapid advancement of Generative Artificial Intelligence (GAI) models presents a new opportunity to automate and accelerate this process. This study evaluated the potential of GAI models to produce craniofacial anatomy illustrations for educational purposes. Methods: Four GAI models, including Midjourney v6.0, DALL-E 3, Gemini Ultra 1.0, and Stable Diffusion 2.0 were used to generate 736 images across multiple views of surface anatomy, bones, muscles, blood vessels, and nerves of the cranium in both oil painting and realistic photograph styles. Four reviewers evaluated the images for anatomical detail, aesthetic quality, usability, and cost-effectiveness. Inter-rater reliability analysis assessed evaluation consistency. Results: Midjourney v6.0 scored highest for aesthetic quality and cost-effectiveness, and DALL-E 3 performed best for anatomical detail and usability. The inter-rater reliability analysis demonstrated a high level of agreement among reviewers (ICC = 0.858, 95% CI). However, all models showed significant flaws in depicting crucial anatomical details such as foramina, suture lines, muscular origins/insertions, and neurovascular structures. These limitations were further characterized by abstract depictions, mixing of layers, shadowing, abnormal muscle arrangements, and labeling errors. Conclusions: These findings highlight GAI’s potential for rapidly creating craniofacial anatomy illustrations but also its current limitations due to inadequate training data and incomplete understanding of complex anatomy. Refining these models through precise training data and expert feedback is vital. Ethical considerations, such as potential biases, copyright challenges, and the risks of propagating inaccurate information, must also be carefully navigated. Further refinement of GAI models and ethical safeguards are essential for safe use.
Whole-genome sequence of Potamopyrgus antipodarum —a model system for the maintenance of sexual reproduction—reveals a recent whole-genome duplication
Jalinsky, Joseph , McElroy, Kyle E. , Sharbrough, Joel , Fields, Peter D. , Higgins, Chelsea , Toll, Cynthia , Boore, Jeffrey L. , Logsdon, John M. , Neiman, Maurine , Bankers, Laura

Mayo Clinic

No container title available | March 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.16.643514 Get It

Abstract Key unanswered questions in biology center on the causes, consequences, and maintenance of sexual reproduction (“sex”). Genome-driven processes are central to the evolutionary and genetic mechanisms inherent to sex, making genomic resources a fundamental part of answering these questions. We present the first genome assembly for a species that is uniquely well-suited for the study of (a)sex in nature, Potamopyrgus antipodarum . This New Zealand snail is unusual in featuring multiple separate transitions from obligately sexual to obligately asexual reproduction, leading to the coexistence of phenotypically similar sexual and asexual forms, a feature that is required to directly study the maintenance of sex. These separately derived asexual lineages constitute separate evolutionary experiments, providing a powerful means of characterizing how the absence of sex affects genome evolution. Our genome assembly provides critical steps towards understanding causes and consequences of sex in this system and important resources for the rapidly growing P. antipodarum and molluscan genomics research community. In characterizing this genome, we uncovered unexpected evidence for a recent whole-genome duplication (WGD) in P. antipodarum . This discovery sets the stage for using P . antipodarum to evaluate processes of rediploidization following WGD and assess whether WGD might drive transitions to asexuality.
A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes
Beck, Roy W. , Aktürk, Halis Kaan , Rizvi, Shafaq , Kudva, Yogish C. , Blevins, Thomas , Church, Mei Mei , Manessis, Anastasios , Calhoun, Peter , Ruedy, Katrina J., Group, for the INHALE-3 Study, Akturk, Halis K , Rizvi, Shafaq Raza , Kudva, Yogish C. , Calhoun, Peter , Hirsch, Irl B , INHALE-3 Study Group , Beck, Roy W , Hirsch, Irl B. , Group, for the INHALE-3 Study

Mayo Clinic

Diabetes Technology & Therapeutics | March 18, 2025 | Volume: 27 | Issue: 3 | Pages: 161-169

10.1089/dia.2024.0581 | PMID 40098469 Get It

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Banerjee, Rahul , Richards, Alicia, Midha, Shonali , Afrough, Aimaz , Anwer, Faiz , Atanackovic, Djordje , Bachanová, Veronika , Bhurtel, Jenny , Cicero, Kara I. , Davis, James A. , Dhakal, Binod , Ferreri, Christopher J. , Forsberg, Peter A. , Freeman, Ciara L. , Khouri, Jack , Kumar, Anupama, Liu, Yuxin , Mikkilineni, Lekha , Peres, Lauren C. , Purvey, Sneha , Raza, Shahzad , Sborov, Douglas W. , Shune, Leyla , Wagner, Charlotte B , Zanwar, Saurabh , Sidana, Surbhi , Patel, Krina K. , Kumar, Shaji , Lin, Yi , Martin, Thomas G. , Voorhees, Peter M. , Anderson, Larry D. , Cowan, Andrew J., Chhabra, Saurabh , Davis, James A , Dhakal, Binod , Freeman, Ciara L , Herr, Megan M. , Jain, Tania , Khouri, Jack , Kocoglu, Mehmet H , McGuirk, Joseph , Parrondo, Ricardo D , Pasvolsky, Oren , Sborov, Douglas W , Wagner, Charlotte , Zanwar, Saurabh S , Sidana, Surbhi , Patel, Krina , Kumar, Shaji K , Voorhees, Peter , Anderson, Larry D , Kaur, Gurbakhash , Bachanova, Veronika , Banerjee, Rahul , Raza, Shahzad , Anwer, Faiz , Atrash, Shebli , Beitinjaneh, Amer , Puglianini, Omar Castañeda , Chhabra, Saurabh , Dima, Danai , Jain, Tania , Janakiram, Murali , Kocoglu, Mehmet H. , Locke, Frederick L. , McGuirk, Joseph P. , Nadeem, Omar , Pasvolsky, Oren , Reshef, Ran , Richard, Shambavi , Rossi, Adriana , Hansen, Doris K. , Kaur, Gurbakhash

Mayo Clinic

Blood Advances | March 15, 2025 | Volume: 9 | Issue: 9 | Pages: 2336-2340

10.1182/bloodadvances.2025016131 | PMID 40088469 Get It

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Shah, Meera , Hung, Kevin , Baranwal, Anmol , Al‐Kali, Aref , Toop, Carla , Greipp, Patricia T. , Brown, Anna , Shah, Syed Naseem, Khanna, Shreyas, Ladon, Dariusz, Gannamani, Vedavyas, Begna, Kebede H. , Price, Zoe, Rud, Danielle, Litzow, Mark R. , Bardy, Peter, Badar, Talha , Kumar, Sharad , Patnaik, Mrinal M. , Foran, James M. , He, Rong , Gangat, Naseema , Scott, Hamish S. , Mangaonkar, Abhishek A. , Hahn, Christopher N , Tefferi, Ayalew , Hiwase, Devendra , Shah, Mithun V , Kutyna, Monika M , Al-Kali, Aref , Toop, Carla , Greipp, Patricia T , Brown, Anna L , Begna, Kebede , Litzow, Mark R. , Hogan, William J , Badar, Talha , Kumar, Sharad , Patnaik, Mrinal , He, Rong , Gangat, Naseema , Scott, Hamish , Arana Yi, Cecilia , Hahn, Christopher , Arber, Daniel A , Kok, Chung H , Hiwase, Devendra , Baranwal, Anmol , Hung, Kevin , Kutyna, Monika , Chen, Dong , Price, Zoe K. , Hogan, William J. , Yeung, David , Yi, Cecilia Arana , Alkhateeb, Hassan B. , THOMAS, DANIEL W. , Orazi, Attilio , Arber, Daniel A. , Kok, Chung Hoow

Mayo Clinic

Blood Advances | March 14, 2025 | Volume: 9 | Issue: 13 | Pages: 3370-3380

10.1182/bloodadvances.2024015238 | PMID 40085954 Get It

Abstract This retrospective analysis aimed to provide evidence-based risk stratification of TP53-mutated (TP53mut) myeloid neoplasms (MNs). Of 580 MNs harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92 (15.9%), and 75 (12.9%) were classified as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) with low blasts (MDS-LB), MDS with excess blasts (MDS-EB)-2, and -EB1 according to the revised fourth edition of the World Health Organization (WHO) classification, respectively. Hierarchical analysis identified the following 4 risk groups with distinct survival: (1) MDS-LB, (2) MDS-EB1/EB2/AML VAF &lt;10%, (3) MDS-EB1/EB2 VAF ≥10%, and (4) AML VAF ≥10%. We next evaluated the impact of allelic status, VAF, and complex karyotype (CK). In our cohort, the significance of biallelic status was limited to MDS with &lt;5% blasts and not for blasts 5% to 9%, as proposed by the International Consensus Classification (ICC), or 5% to 19%, as proposed by the fifth edition of the WHO (WHO-5). MDS-EB1 and -EB2 with VAF ≥10% had comparable survival (9.6 vs 7.2 months; P = .12), regardless of allelic status. Contrary to the ICC proposal, MDS-EB1/EB2 with VAF &lt;10% and CK had poor survival compared with those without CK, comparable to MDS-EB1/EB2 with VAF ≥10% (5.6 vs 26.2 vs 6.3 months; P = .003). Survival of TP53mut AML was poor (median 3.9 months) regardless of allelic/CK status. Thus, using ICC or WHO-5 may underestimate prognosis of MDS with blasts 5% to 19% and 5% to 9%, respectively. Collectively, the hierarchical model acknowledges poor survival of 91.9% TP53mut MDS and AML compared with 36.5% and 80.7% by WHO-5 and ICC, respectively.